AstraZeneca Completes Key Drug Interaction Study for Capivasertib, Easing Safety Overhang
AstraZeneca ($~AZN) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AstraZeneca (AZN) has completed a Phase 1 study titled “An Open-label, Fixed-sequence Study to Assess the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants.” The goal was to see how capivasertib changes the way the body handles rosuvastatin, a common cholesterol drug, which matters for future combination use in cancer patients.
The study tested two oral drugs: capivasertib, AstraZeneca’s AKT inhibitor under development for cancer, and rosuvastatin, a widely used statin sold as Crestor. The aim was not to test cancer benefit, but to check if capivasertib affects rosuvastatin levels in the body in a way that could raise safety concerns or require dose changes.
The trial used an interventional design in healthy volunteers with a simple, fixed sequence. Everyone first received a single dose of rosuvastatin, then after a washout period they received capivasertib together with rosuvastatin, with an extra dose of capivasertib 12 hours later. The study was open-label, meaning both participants and investigators knew which drugs were given, and the main purpose was to study drug interaction.
The study is listed as Phase 1 and interventional, with no random assignment and no blinding, which is typical for a focused drug–drug interaction study. The primary objective was to measure how capivasertib changes rosuvastatin exposure, using standard blood sampling and concentration tracking over time, rather than clinical outcomes.
The trial has an overall status of “Completed,” which means dosing and follow-up are finished. The study was first submitted to the registry on July 17, 2025, and the most recent update was filed on March 2, 2026, signaling that AstraZeneca has refreshed the record, likely to reflect completion and updated protocol or timing details.
The primary completion date marks when main data on the interaction were collected, while the estimated overall completion date signals when all study activities and analyses are expected to wrap. Although specific calendar dates are not detailed in the summary, the completed status and the 2026-03-02 update show the study has moved past data collection and closer to internal readout.
For investors, this update reduces regulatory and safety uncertainty around capivasertib’s use alongside statins, a common background therapy in oncology patients. A clean interaction profile would support broader real-world use and smoother labeling discussions, which can in turn help de-risk AstraZeneca’s late-stage capivasertib program and modestly support sentiment around AZN.
Competitors in targeted oncology, including Pfizer, Novartis, and others pursuing AKT and related pathway inhibitors, also face the same scrutiny on drug interactions. AstraZeneca’s visible progress and timely updates help position capivasertib as a more “practice-ready” asset, even as the market waits for pivotal efficacy readouts to drive any major re-rating in the stock.
While this Phase 1 interaction study alone is unlikely to move the share price in a big way, it feeds into the broader risk-benefit picture of the capivasertib franchise and supports AstraZeneca’s reputation for disciplined development. The completed status and fresh listing update on ClinicalTrials.gov confirm that the program is advancing on schedule and that further details are available on the ClinicalTrials portal.
To learn more about ~AZN’s potential, visit the AstraZeneca drug pipeline page.
